当前位置: 首页 > 期刊 > 《中国药房》 > 20187
编号:13592978
GSTP1rs1695基因多态性与自体造血干细胞移植患者血液学毒性的关系研究(4)
http://www.100md.com 2018年4月1日 《中国药房》 20187
     [10] DASGUPTA RK, ADAMSON PJ, DAVIES FE, et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma[J]. Blood,2003,102(7): 2345-2350.

    [11] ZHONG S, HUANG M, YANG X, et al. Relationship of glutathione-S-transferase genotypes with side effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus[J]. Br J Clin Pharmacol,2006,62(4):457-472.

    [12] ISLAM MS, ISLAM MS, PARVIN S, et al. Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil- based chemotherapy in Bangladeshi breast cancer patients[J]. Tumour Biol,2015,36(7):1-7.

    [13] SUGISHITA M, IMAI T, KIKUMORI T, et al. Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer[J]. Breast Cancer,2016,23(2):195- 201.

    [14] JAMIESON D, LEE J, CRESTI N, et al. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil[J]. Cancer Chemother Pharmacol,2014,74(4):667-674.

    (收稿日期:2017-11-07 修回日期:2018-02-01)

    (編辑:邹丽娟), 百拇医药(张关敏 刘卫平 马旭 朱军 王小沛 张艳华)
上一页1 2 3 4